Prognostic Signature

A prognostic signature is a pattern of molecular, clinical, or imaging features used to estimate a patient’s likely disease course, such as survival, recurrence, or treatment response. In cancer research, investigators combine measurements from tumors or patients and use statistical or computational models to identify features associated with outcomes, then validate the resulting signature in independent groups. Prognostic signatures can stratify patients into risk categories, support study design, and clarify biological differences among cancers. When rigorously validated, they may improve patient counseling and help guide surveillance or treatment decisions, while also providing a framework for developing more precise cancer research and care.

Prognostic Signature - Related Videos

Research

JoVE Journal - Environment
Free Sample

Evaluating the Impact of Hydraulic Fracturing on Streams using Microbial Molecular Signatures

0 Views •

Cited by 1 •

2021

Here, we present a protocol to investigate the impacts of hydraulic fracturing on nearby streams by analyzing their water and sediment microbial communities.

Research

JoVE Journal - Biology

Reconstruction of Single-Cell Innate Fluorescence Signatures by Confocal Microscopy

0 Views •

Cited by 1 •

2020

Here, a protocol is presented for optically extracting and cataloging innate cellular fluorescence signatures (i.e., cellular autofluorescence) from every individual live cell distributed in a three-dimensional space. This method is suitable for studying the innate fluorescence signature of diverse biological systems at a single-cell resolution, including cells from bacteria, fungi, yeasts, plants, and animals.

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

0 Views •

Cited by 42 •

2020

Breast cancer related lymphedema is frequent in breast cancer survivors, but there are not widely employed guidelines for its diagnosis and quantification. Here, we introduce a reliable and cost-effective protocol to define, quantify, and compare upper limb volume in breast cancer patients.

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

0 Views •

Cited by 34 •

2017

Here, we present the detailed protocol adopted in the BioMILD screening trial to perform the circulating microRNA signature classifier test for early lung cancer detection.

Research

JoVE Journal - Cancer Research

Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

0 Views •

Cited by 2 •

2023

Utilizing an immunocompetent, autochthonous tumor model driven by common patient mutations for preclinical testing is critical for immunotherapeutic testing. This protocol describes a method to generate brain tumor mouse models using electroporation-based delivery of plasmid DNA that represent common patient mutations, thus providing an accurate, reproducible, and consistent mouse model.

View All Results

FAQs

Related Topics